| Literature DB >> 27092342 |
A I Graul1, E Cruces2, C Dulsat2, M Tracy2.
Abstract
This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M&A. We also take a look into the crystal ball and anticipate the new drugs that may reach the market in 2016. Copyright 2016 Prous Science, S.A.U. or its licensors. All rights reserved.Entities:
Keywords: Discontinuations; Drug pricing; FDA; Orphan drug; Priority review; Voucher
Mesh:
Substances:
Year: 2016 PMID: 27092342 DOI: 10.1358/dot.2016.52.2.2472346
Source DB: PubMed Journal: Drugs Today (Barc) ISSN: 1699-3993 Impact factor: 2.245